The application of antidepressant drugs in cancer treatment

Zheng, Yunxi; Chang, Xu; Huang, Yufei; He, Dingwen

doi:10.1016/j.biopha.2022.113985

Cited by 21 publications

(15 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anticancer activity of sertraline, paroxetine, and chlorpromazine on different cancer cell lines was previously described. Sertraline was found to be effective against several human cancer cell lines ([ 15 , 38 , 39 , 40 , 41 , 42 , 43 ] reviewed in [ 19 ]) ( Table 3 ). Through the comparison of the values obtained for those cells with UM-UC-5 ( Table 2 ), it is possible to observe that the latter are more sensitive to STL.…”

Section: Discussionmentioning

confidence: 99%

A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5

Gouveia,

Ribeiro,

Vale

2024

Pharmaceutics

View full text Add to dashboard Cite

The potential benefits of drug repurposing have gained attention as an alternative to developing de novo drugs. The potential of using central nervous system (CNS) drugs as anticancer drugs has been explored in several types of human cancers, such as breast and colon cancer, among others. Here, we examine the effect of the CNS drugs sertraline, paroxetine, and chlorpromazine on human squamous carcinoma cells of the bladder (UM-UC-5). After exposing UM-UC-5 cells to increased concentrations of each drug for 48 h, we assessed their metabolic activity using an MTT assay. Based on those results, we calculated cell viability and the half-maximal inhibitory concentration (IC50) values. The results suggest that the CNS drugs were effective against UM-UC-5 in the order of potency of sertraline > chlorpromazine > paroxetine. Interestingly, sertraline was more potent than 5-fluorouracil (5-FU), a widely used anticancer drug. This study demonstrated, for the first time, the promising anticancer activity of CNS drugs on human bladder cancer cells in vitro and supports the repurposing of CNS drugs to improve cancer treatment. Nevertheless, further studies are necessary to understand their mechanism of action and in vivo activity.

show abstract

Section: Discussionmentioning

confidence: 99%

A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5

Gouveia,

Ribeiro,

Vale

2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…This is the case in colon-cancer , in which the use of fluoxetine inhibits the transcriptional activity of NF-kappa B, and the proliferation of cells [ 58 ]. In addition, in general, the use of these drugs does not present a large number of side effects in the organism [ 59 ]. Therefore, taking into account the fact that treatment with antidepressant drugs after a cancer diagnosis is quite frequent, if it is possible to perform both treatments with the same drug, as is the case with agomelatine, conferring a double benefit.…”

Section: Discussionmentioning

confidence: 99%

Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer

et al. 2023

View full text Add to dashboard Cite

The potential use of agomelatine as an alternative treatment for colorectal cancer is evaluated in this work. The effect of agomelatine was studied in an in vitro model using two cell lines with different p53 statuses (HCT-116, wild-type p53, and HCT-116 p53 null) and an in vivo xenograft model. The inhibitory effects of agomelatine and melatonin were stronger in the cells harboring the wild-type p53, although in both cell lines, the effect of agomelatine was greater than that of the melatonin. In vivo, only agomelatine was able to reduce the volumes of tumors generated by the HCT-116-p53-null cells. Both treatments induced changes in the rhythmicity of the circadian-clock genes in vitro, albeit with some differences. Agomelatine and melatonin regulated the rhythmicity of Per1-3, Cry1, Sirt1, and Prx1 in the HCT-116 cells. In these cells, agomelatine also regulated Bmal1 and Nr1d2, while melatonin changed the rhythmicity of Clock. In the HCT-116-p53-null cells, agomelatine regulated Per1-3, Cry1, Clock, Nr1d2, Sirt1, and Prx1; however, melatonin only induced changes in Clock, Bmal1, and Sirt1. The differences found in the regulation of the clock genes may explain the greater oncostatic effect of agomelatine in CRC.

show abstract

“…However, their evidence of efficacy, long-term use [25], and personalised precision medicine [26] remain inadequate [27]. There is some evidence showing that immunosuppressive and chemotherapeutic resistance (chemoresistance) developed into immune evasion and multidrug resistance (MDR), respectively [28][29] [30]. Despite these well-known immunotherapies, immune evasion, and chemoresistance, OS metastasis remains the primary barrier to achieving therapy efficacy [8].…”

Section: Of 26mentioning

confidence: 99%

Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance

Zaidi¹,

Haque²,

Miskon³

2023

Preprint

View full text Add to dashboard Cite

There has been no significant efficacy in treatment for osteosarcoma (OS) metastasis after nearly four decades of trials. This motivates us to elucidate OS therapies according to their four bidirectional mutation stages. To refresh the OS therapy status quo, the historical developments and clinical advancements are briefly described. However, the main issue of metastasis remains unresolved, accounting for 90% of pulmonary metastasis deaths. Thus, this metastasis problem is related to immune evasion and chemoresistance that are being induced after long-term treatment by the use of immunotherapy for tumorigenesis. Therefore, it is rationale to discuss the relationship cycles of mutation stages including tumorigenesis, metastasis, immune evasion, and chemoresistance. Even though many combinational and targeted therapies have been developed to intensify these mutation treatments, successful clinical translations with higher cure rates are still rare. Through this review, an in-depth understanding of the bidirectional relationship between the four OS mutation stages and their respective therapies is provided. Herein, we summarise the medicines used to treat tumorigenesis, including COLGALT2 inhibitors, Tra2B, and AGAP1, miR-148a and miR-21-5p EVs, and the lncRNA LIFR-AS1. Following the medicines used to treat metastasis are AXL, miR-135a-5p, mRNA BCL6, TGFβ1, Tim-3, SOCS5, CASC15, KLF3-AS1, PDCD4, ATG5, and Rab22a-NeoF1. Then the medicines used to treat immune evasion are N-cadherin, anti-IL-9, USP12 inhibitor, IgG-4+ B-cells, LAP inhibitor, anti-Wnt2 mAb, anti-αvβ8 integrin, HK2-mediated IκBα, IDO inhibitor with NO, and TGF-βRII with anti-IgG1. Finally, the medicines used to treat chemoresistance are DHFR, FPGS, HSP-90AA1, XCT-790, ATKI, and IGF1. As a result, this contribution is expected to serve as a reference and guide for scientists and clinicians.

show abstract

The application of antidepressant drugs in cancer treatment

Cited by 21 publications

References 106 publications

A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5

A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5

Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer

Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance

Contact Info

Product

Resources

About